NEORNAT
Latest round
- Series A
Last raised
- Mar 2022
Total raised
- $2.5M
Investors
- 5
About NEORNAT
Founded in 2020 and based in Seoul, South Korea, NEORNAT specializes in the development of macrophage immuno-oncology drugs and RNA regulator-targeted anticancer drugs. The company develops liver cancer-specific RNAi treatment, RNA control-based liver cancer-targeting anticancer drug development proceeds, and multi-marker panel for whole-cycle liver disease diagnosis based on big data., RT-SMAR, and RD-LCMD.
Who invested in NEORNAT
5 investors across 1 round
See all investors in NEORNAT
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 29, 2022
Amount
$2.5M
Investors
Questions about NEORNAT
Who invested in NEORNAT?
NEORNAT has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NEORNAT raised?
NEORNAT has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NEORNAT last raise money?
NEORNAT's most recent round on record is a Series A, in Mar 2022.
What does NEORNAT do?
Founded in 2020 and based in Seoul, South Korea, NEORNAT specializes in the development of macrophage immuno-oncology drugs and RNA regulator-targeted anticancer drugs.
Where is NEORNAT headquartered?
NEORNAT is headquartered in Seoul, South Korea.
Which VCs invest in companies like NEORNAT?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at NEORNAT's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like NEORNAT? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.